Viviana Sánchez-Encinales

Viviana Sánchez-Encinales

Auto-generated profile, based on publicly available information

Viviana Sánchez-Encinales

From the Microbiology Department, Donostia University Hospital-Biodonostia Health Research Institute, Donostia-San Sebastian

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
YSYounes Smani
Younes Smani
AFAnna Fàbrega
Anna Fàbrega
Ignasi RocaIgnasi Roca
Ignasi Roca
VSViviana Sánchez-Encinales
Viviana Sánchez-Encinales
Jordi VilaJordi Vila
Jordi Vila
JPJerónimo Pachón
Jerónimo Pachón
Acinetobacter baumannii has emerged as a nosocomial pathogen with an increased prevalence of multidrug-resistant strains. The role of the outer membrane protein A (OmpA) in antimicrobial resistance remains poorly understood. In this report, disruption of the ompA gene led to decreased MICs of chloramphenicol, aztreonam, and nalidixic acid. We have characterized, for the first time, the contribution of OmpA in the antimicrobial resistance phenotype of A. baumannii .

15 July 2013 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
FGFrancisco Visiedo García
Francisco Visiedo García
FBFernando Bugatto
Fernando Bugatto
VSViviana Sánchez
Viviana Sánchez
ICIrene Cozar-Castellano
Irene Cozar-Castellano
JBJose L. Bartha
Jose L. Bartha
German PerdomoGerman Perdomo
German Perdomo
Placentas of women with gestational diabetes mellitus (GDM) exhibit an altered lipid metabolism. The mechanism by which GDM is linked to alterations in placental lipid metabolism remains obscure. We hypothesized that high glucose levels reduce mitochondrial fatty acid oxidation (FAO) and increase triglyceride accumulation in human placenta. To test this hypothesis, we measured FAO, fatty acid esterification, de novo fatty acid synthesis, triglyceride levels, and carnitine palmitoyltransferase activities (CPT) in placental explants of women with GDM or no pregnancy complication. In women with GDM, FAO was reduced by ∼30% without change in mitochondrial content, and triglyceride content was threefold higher than in the control group. Likewise, in placental explants of women with no complications, high glucose levels reduced FAO by ∼20%, and esterification increased linearly with increasing fatty acid concentrations. However, de novo fatty acid synthesis remained unchanged between high and low glucose levels. In addition, high glucose levels increased triglyceride content approximately twofold compared with low glucose levels. Furthermore, etomoxir-mediated inhibition of FAO enhanced esterification capacity by ∼40% and elevated triglyceride content 1.5-fold in placental explants of women, with no complications. Finally, high glucose levels reduced CPT I activity by ∼70% and phosphorylation levels of acetyl-CoA carboxylase by ∼25% in placental explants of women, with no complications. We reveal an unrecognized regulatory mechanism on placental fatty acid metabolism by which high glucose levels reduce mitochondrial FAO through inhibition of CPT I, shifting flux of fatty acids away from oxidation toward the esterification pathway, leading to accumulation of placental triglycerides.

31 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XVXavier Vila-Farrés
Xavier Vila-Farrés
RPRaquel Parra-Millán
Raquel Parra-Millán
VSViviana Sánchez-Encinales
Viviana Sánchez-Encinales
MVMonica Varese
Monica Varese
RARafael Ayerbe-Algaba
Rafael Ayerbe-Algaba
YSYounes Smani
Younes Smani
Preventing the adhesion of pathogens to host cells provides an innovative approach to tackling multidrug-resistant bacteria. In this regard, the identification of outer membrane protein A (OmpA) as a key bacterial virulence factor has been a major breakthrough. The use of virtual screening helped us to identify a cyclic hexapeptide AOA-2 that inhibits the adhesion of Acinetobacter baumannii, Pseudomonas aeruginosa and Escherichia coli to host cells and the formation of biofilm, thereby preventing the development of infection in vitro and in a murine sepsis peritoneal model. Inhibition of OmpA offers a strategy as monotherapy to address the urgent need for treatments for infections caused by Gram-negative bacilli.

3 October 2018 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
RARafael Ayerbe-Algaba
Rafael Ayerbe-Algaba
MGMaría Luisa Gil-Marqués
María Luisa Gil-Marqués
MJManuel E. Jiménez-Mejías
Manuel E. Jiménez-Mejías
VSViviana Sánchez-Encinales
Viviana Sánchez-Encinales
RPRaquel Parra-Millán
Raquel Parra-Millán
YSYounes Smani
Younes Smani
Colistin is among the few antibiotics effective against multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae clinical isolates. However, in the last few years, colistin-resistant A. baumannii and K. pneumoniae strains have emerged. Therefore, combination therapies, between colistin and other old drugs, restoring the activity of colistin are required. The main objective of this study was to analyse the activity of niclosamide, an anthelmintic drug, in combination with colistin against colistin-susceptible (Col-S) and colistin-resistant (Col-R) A. baumannii and K. pneumoniae. The MIC were determined by microdilution assay and the time-kill curves were performed. The zeta potential of Col-S and Col-R of A. baumannii and K. pneumoniae in presence of niclosamide was assessed. Niclosamide in combination with colistin showed improved activity against Col-S and Col-R A. baumannii and K. pneumoniae. Time-killing curves showed synergic activity between niclosamide and colistin against Col-S and Col-R A. baumannii and K. pneumoniae, especially when niclosamide or colistin was added for second time at 4 h of the 24 h killing curve. Col-R A. baumannii and K. pneumoniae in presence of niclosamide exhibited a greater negative charge (−34.95 ± 0.35 mV and −38.85 ± 0.92 mV; P < 0.05) than Col-R A. baumannii and K. pneumoniae in absence of niclosamide (−26.85 ± 3.65 mV and −35.27 ± 0.72 mV). These data suggest that niclosamide might be combined with colistin, being a potential alternative for treatment of Col-R Gram-negative bacilli infections.

24 January 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
VSViviana Sánchez-Encinales
Viviana Sánchez-Encinales
RARocio Alvarez-Marin
Rocio Alvarez-Marin
MPMaría Eugenia Pachón-Ibáñez
María Eugenia Pachón-Ibáñez
FFFelipe Fernández-Cuenca
Felipe Fernández-Cuenca
APAlvaro Pascual
Alvaro Pascual
YSYounes Smani
Younes Smani
Outer membrane protein A (OmpA) is a porin involved in Acinetobacter baumannii pathogenesis. However, OmpA clinical implication in hospital-acquired infections remains unknown. We aimed to determine whether OmpA overproduction was a risk factor associated with pneumonia, bacteremia, and mortality. We analyzed demographic, microbiological, and clinical data from 100 patients included in a unicenter cohort and 246 included in a unicenter cohort and a multicenter cohort. Representative isolates were classified into 2 groups: (1) isolates from patients colonized by A. baumannii (16 from the unicenter and 20 from the multicenter cohort) and (2) isolates from bacteremic or nonbacteremic patients with pneumonia (PP) caused by A. baumannii (13 from the unicenter and 23 from the multicenter cohort) Expression of ompA was determined with quantitative reverse-transcription polymerase chain reaction. Isolates from PP overexpressed more ompA than those from colonized patients from the unicenter (ratio, 1.76 vs 0.36; P < .001) and the multicenter (1.36 vs 0.91; P = .03) cohorts. Among isolates from PP, those from bacteremic patients overexpressed nonsignificantly more ompA than those from nonbacteremic patients in the unicenter (ratio, 2.37 vs 1.43; P = .06) and the multicenter (2.03 vs 0.91; P = .14) cohorts. Multivariate analysis in both cohorts together showed ompA overexpression as independent risk factor for pneumonia (P < .001), bacteremia (P = .005), and death (P = .049). These data suggest that ompA overexpression is an associated factor for pneumonia, bacteremia, and death due to A. baumannii.

1 August 2016 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RMR. Parra Millán
R. Parra Millán
MMM. E. Jiménez Mejías
M. E. Jiménez Mejías
VEV. Sánchez Encinales
V. Sánchez Encinales
RAR. Ayerbe Algaba
R. Ayerbe Algaba
AGalicia Gutierrez-Valencia
alicia Gutierrez-Valencia
YSYounes Smani
Younes Smani
Immune response stimulation to prevent infection progression may be an adjuvant to antimicrobial treatment. Lysophosphatidylcholine (LPC) is an immunomodulator involved in immune cell recruitment and activation. In this study, we aimed to evaluate the efficacy of LPC in combination with colistin, tigecycline, or imipenem in experimental murine models of peritoneal sepsis and pneumonia. We used Acinetobacter baumannii strain Ab9, which is susceptible to colistin, tigecycline, and imipenem, and multidrug-resistant strain Ab186, which is susceptible to colistin and resistant to tigecycline and imipenem. Pharmacokinetic and pharmacodynamic parameters for colistin, tigecycline, and imipenem and the 100% minimal lethal dose (MLD 100 ) were determined for both strains. The therapeutic efficacies of LPC, colistin (60 mg/kg of body weight/day), tigecycline (10 mg/kg/day), and imipenem (180 mg/kg/day), alone or in combination, were assessed against Ab9 and Ab186 at the MLD 100 in murine peritoneal sepsis and pneumonia models. The levels of pro- and anti-inflammatory cytokines, i.e., tumor necrosis factor alpha (TNF-α) and interleukin-10 (IL-10), were determined by enzyme-linked immunosorbent assay (ELISA) for the same experimental models after inoculating mice with the MLD of both strains. LPC in combination with colistin, tigecycline, or imipenem markedly enhanced the bacterial clearance of Ab9 and Ab186 from the spleen and lungs and reduced bacteremia and mouse mortality rates ( P < 0.05) compared with those for colistin, tigecycline, and imipenem monotherapies. Moreover, at 4 h post-bacterial infection, Ab9 induced higher TNF-α and lower IL-10 levels than those with Ab186 (4 μg/ml versus 3 μg/ml [ P < 0.05] and 2 μg/ml versus 3.4 μg/ml [ P < 0.05], respectively). LPC treatment combined with colistin, tigecycline, or imipenem modestly reduced the severity of infection by A. baumannii strains with different resistance phenotypes compared to LPC monotherapy in both experimental models.